Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Lagerbericht

Marktkapitalisierung: US$12.4b

Ionis Pharmaceuticals Management

Management Kriterienprüfungen 4/4

Ionis Pharmaceuticals CEO ist Brett Monia , ernannt in Jan 2020, hat eine Amtszeit von 6.33 Jahren. Die jährliche Gesamtvergütung beträgt $13.35M , bestehend aus 7.9% Gehalt und 92.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.15% der Aktien des Unternehmens, im Wert von $18.27M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.3 Jahre bzw. 10 Jahre.

Wichtige Informationen

Brett Monia

Geschäftsführender

US$13.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts7.88%
Amtszeit als Geschäftsführer6.3yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements6.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder10yrs

Jüngste Management Updates

Recent updates

Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile

Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.

IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile

Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.

IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook

Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative

Mar 20

IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations

Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.

IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile

Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.

IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook

Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.

IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis

Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.

IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile

Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.

IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook

Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.

IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook

Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.

IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.

IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins

The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.

Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Ionis Pharmaceuticals’ consensus price target edged up to $59.19 as analysts cited favorable FDA approval and label for Dawnzera in hereditary angioedema, strong initial launches, and growing pipeline confidence as key drivers, outweighing modest concerns on Wainua revenues. Analyst Commentary FDA approval of Dawnzera with a favorable, broad label (including both every four and eight week dosing) and absence of major safety warnings, positioning it competitively against Takhzyro and Andembry in hereditary angioedema.

Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Aug 01
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Jul 30
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

Jul 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22
User avatar

Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage

Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs.

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Brett Monia im Vergleich zu den Einnahmen von Ionis Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$327m

Dec 31 2025US$13mUS$1m

-US$381m

Sep 30 2025n/an/a

-US$256m

Jun 30 2025n/an/a

-US$268m

Mar 31 2025n/an/a

-US$458m

Dec 31 2024US$15mUS$1m

-US$454m

Sep 30 2024n/an/a

-US$359m

Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Vergütung im Vergleich zum Markt: BrettDie Gesamtvergütung ($USD13.35M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD14.60M).

Entschädigung vs. Einkommen: BrettDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Brett Monia (64 yo)

6.3yrs
Amtszeit
US$13,350,777
Vergütung

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Brett Monia
Founder6.3yrsUS$13.35m0.15%
$ 18.3m
Elizabeth Hougen
Executive VP of Finance & CFO13.3yrsUS$4.42m0.050%
$ 6.2m
Patrick O'Neil
Executive VP13.3yrsUS$3.21m0.038%
$ 4.7m
Eric Swayze
Executive Vice President of Research6.3yrsUS$3.23m0.020%
$ 2.5m
Brian Birchler
Executive Vice President of Corporate & Development Operations6.3yrsUS$3.24m0.041%
$ 5.1m
Richard Geary
Strategic Consultantless than a yearUS$3.33m0.036%
$ 4.5m
Eugene Schneider
Executive VP2.7yrskeine Daten0.039%
$ 4.8m
Darren Gonzales
Chief Accounting Officer & Senior VP6.3yrskeine Datenkeine Daten
C. Bennett
Executive VP & Chief Scientific Officer6.3yrsUS$958.87k0.049%
$ 6.1m
D. Walke
Senior Vice President of Investor Relationsno datakeine Datenkeine Daten
Tracy Berns
Senior VP and Chief Compliance & Quality Assurance Officerno datakeine Datenkeine Daten
Hayley Soffer
Vice President of Corporate Communications2.3yrskeine Datenkeine Daten
6.3yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von IONS ist erfahren und erfahren (durchschnittliche Amtszeit von 6.3 Jahren).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Brett Monia
Founder7.2yrsUS$13.35m0.15%
$ 18.3m
B. Parshall
Director25.7yrsUS$538.78k0.031%
$ 3.9m
Joan Herman
Independent Director6.9yrsUS$541.28k0.028%
$ 3.5m
Joseph Klein
Independent Director20.4yrsUS$543.78k0.0067%
$ 837.3k
Joseph Wender
Lead Independent Director32.3yrsUS$598.78k0.031%
$ 3.9m
Michael Hayden
Independent Director7.7yrsUS$528.78k0.034%
$ 4.2m
Spencer Berthelsen
Independent Director24yrsUS$548.78k0.094%
$ 11.8m
Joseph Loscalzo
Independent Chairman of the Board12.3yrsUS$568.78k0.022%
$ 2.7m
Allene Diaz
Independent Director4.9yrsUS$531.28k0.0023%
$ 287.4k
Michael Yang
Independent Director2.4yrsUS$518.78k0.0048%
$ 597.2k
10.0yrs
Durchschnittliche Betriebszugehörigkeit
71yo
Durchschnittliches Alter

Erfahrener Vorstand: IONSDie Vorstandsmitglieder gelten als erfahren (10 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/03 12:41
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Ionis Pharmaceuticals, Inc. wird von 43 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
James BirchenoughBarclays
Eliana MerleBarclays
Huidong WangBarclays